Compare Sun Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA ASTRAZENECA PHARMA SUN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 22.4 94.0 23.8% View Chart
P/BV x 2.6 26.5 9.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
ASTRAZENECA PHARMA
Mar-18
SUN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6791,278 53.1%   
Low Rs375883 42.5%   
Sales per share (Unadj.) Rs121.1228.4 53.0%  
Earnings per share (Unadj.) Rs13.410.4 129.1%  
Cash flow per share (Unadj.) Rs20.716.3 127.2%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.698.8 174.7%  
Shares outstanding (eoy) m2,399.2625.00 9,597.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.7 92.0%   
Avg P/E ratio x39.4104.2 37.8%  
P/CF ratio (eoy) x25.566.4 38.4%  
Price / Book Value ratio x3.110.9 27.9%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,65027,008 4,682.6%   
No. of employees `00017.51.4 1,290.6%   
Total wages/salary Rs m59,6711,535 3,886.6%   
Avg. sales/employee Rs Th16,608.14,210.9 394.4%   
Avg. wages/employee Rs Th3,409.61,132.2 301.1%   
Avg. net profit/employee Rs Th1,833.8191.1 959.7%   
INCOME DATA
Net Sales Rs m290,6595,710 5,090.4%  
Other income Rs m10,255123 8,371.3%   
Total revenues Rs m300,9145,833 5,159.3%   
Gross profit Rs m63,076463 13,626.2%  
Depreciation Rs m17,533147 11,894.5%   
Interest Rs m5,5530-   
Profit before tax Rs m50,246438 11,471.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009179 3,358.7%   
Profit after tax Rs m32,093259 12,386.4%  
Gross profit margin %21.78.1 267.7%  
Effective tax rate %12.040.8 29.3%   
Net profit margin %11.04.5 243.3%  
BALANCE SHEET DATA
Current assets Rs m310,6923,209 9,681.3%   
Current liabilities Rs m173,3962,070 8,378.7%   
Net working cap to sales %47.220.0 236.7%  
Current ratio x1.81.6 115.5%  
Inventory Days Days9972 136.9%  
Debtors Days Days11235 319.5%  
Net fixed assets Rs m232,477790 29,416.3%   
Share capital Rs m2,39950 4,798.6%   
"Free" reserves Rs m411,6912,419 17,017.0%   
Net worth Rs m414,0912,469 16,769.6%   
Long term debt Rs m15,2260-   
Total assets Rs m646,9384,605 14,047.4%  
Interest coverage x10.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.41.2 36.2%   
Return on assets %5.85.6 103.4%  
Return on equity %7.810.5 73.9%  
Return on capital %10.217.7 57.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,025300 22,041.5%   
Fx outflow Rs m38,6102,015 1,916.2%   
Net fx Rs m27,415-1,715 -1,598.2%   
CASH FLOW
From Operations Rs m21,96588 24,988.1%  
From Investments Rs m-6,813-94 7,278.3%  
From Financial Activity Rs m-27,305NA-  
Net Cashflow Rs m-8,442-6 148,096.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 15.7 146.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 12,856 1,034.7%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  BIOCON   

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling; Sensex Down 235 Points(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 22, 2019 03:29 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - PIRAMAL ENTERPRISES COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS